Autoimmune Disease Therapeutics Worldwide: Markets & Developments

Published by: PJB Publications USA Inc.

Published: Jan. 1, 2002 - 450 Pages

Table of Contents

1.1 Scope and Objectives of Reports

1.2 Methodology

1.3 The Emerging World Market for Autoimmune Diseases

1.4 Market Size and Forecast

1.5 Competitor Market Summary

2 Introduction and Overview

2.1 Autoimmunity

2.2 Components of the Immune System

2.2.1 Humoral Immunity

2.2.2 Cell-mediated Immunity

2.3 Types of Autoimmune Diseases

2.3.1 Reclassification of Autoimmune Diseases

2.4 Pathology of Autoimmune Disease

2.5 Prevalence and Demographics of Autoimmune Disease

2.5.1 Higher Prevalence Among Women

3 Issues and Trends in Autoimmune Disease Management

3.1 Women’s Health Issues

3.2 Regulatory and Legislative Actions

3.3 Costs of Treatment

3.4 Genes and the Immune System

3.5 Stem Cell Research

3.5.1 Rebooting

4 Rheumatoid Arthritis

4.1 Pathology of Rheumatoid Arthritis

4.2 Risk Factors for Rheumatoid Arthritis


4.3 Prevalence of Rheumatoid Arthritis

4.4 Diagnostics for Rheumatoid Arthritis

4.4.1 Blood Tests

4.4.2 Radiography (X-Rays)

4.4.3 Other Diagnostic Techniques

4.5 Current Treatments for Rheumatoid Arthritis

4.5.1 Aspirin and Traditional NSAIDs

4.5.2 COX-2 Inhibitors

4.5.3 Corticosteroids

4.5.4 Disease-Modifying Antirheumatic Drugs (DMARDs)

4.5.5 Tumor Necrosis Factor (TNF) Inhibitors

4.5.6 Interleukin 1 Inhibitor

4.5.7 Surgical Treatments

4.6 Treatments in Development for Rheumatoid Arthritis

4.7 Market Analysis for Rheumatoid Arthritis

4.7.1 United States

4.7.2 Europe

4.7.3 Japan

4.7.4 Rest of the World

4.8 Competitor Analysis for Rheumatoid Arthritis

5 Systemic Lupus Erythematosus

5.1 Pathology of Systemic Lupus Erythematosus

5.2 Risk Factors for Systemic Lupus Erythematosus

5.3 Prevalence of Systemic Lupus Erythematosus

5.4 Diagnostics for Systemic Lupus Erythematosus

5.5 Current Treatments for Systemic Lupus Erythematosus

5.5.1 Nonsteroidal Anti-inflammatory Drugs (NSAIDs) 5.5.2 Corticosteroids

5.5.3 Disease-Modifying Antirheumatic Drugs (DMARDs)

5.6 Treatments in Development for Systemic Lupus Erythematosus

5.7 Market Analysis for Systemic Lupus Erythematosus

5.7.1 United States

5.7.2 Europe

5.7.3 Japan

5.7.4 Rest of the World

5.8 Competitor Analysis for Systemic Lupus Erythematosus

6 Inflammatory Bowel Disease

6.1 Pathology of Inflammatory Bowel Disease

6.1.1 Ulcerative Colitis

6.1.2 Crohn’s Disease

6.2 Risk Factors for Inflammatory Bowel Disease

6.3 Prevalence of Inflammatory Bowel Disease

6.4 Diagnostics for Inflammatory Bowel Disease

6.5 Current Treatments for Inflammatory Bowel Disease

6.5.1 Mesalamine and Sulfasalazine

6.5.2 Corticosteroids

6.5.3 Disease-Modifying Antirheumatic Drugs (DMARDs)

6.5.4 Antibiotics

6.5.5 Tumor Necrosis Factor (TNF) Inhibitors

6.5.6 Surgical Treatments

6.6 Treatments in Development for Inflammatory Bowel Disease

6.7 Market Analysis for Inflammatory Bowel Disease

6.7.1 United States

6.7.2 Europe

6.7.3 Japan

6.7.4 Rest of the World

6.8 Competitor Analysis for Inflammatory Bowel Disease

7 Psoriasis

7.1 Pathology of Psoriasis

7.1.1 Types of Psoriasis

7.2 Risk Factors for Psoriasis

7.3 Prevalence of Psoriasis

7.5 Current Treatments for Psoriasis

7.5.1 Topical Medications

7.5.2 Phototherapy

7.5.3 Systemic Medications

7.6 Treatments in Development for Psoriasis

7.7 Market Analysis for Psoriasis

7.7.1 United States

7.7.2 Europe

7.7.3 Japan

7.7.4 Rest of the World

7.8 Competitor Analysis for Psoriasis

8 Multiple Sclerosis

8.1 Pathology of Multiple Sclerosis

8.1.1 Types of Multiple Sclerosis

8.2 Risk Factors for Multiple Sclerosis

8.2.1 Infection

8.2.2 Genetic Factors

8.3 Prevalence of Multiple Sclerosis

8.4 Diagnostics for Multiple Sclerosis

8.5 Current Treatments for Multiple Sclerosis

8.5.1 Symptomatic Treatments

8.5.2 Causative Treatments

8.6 Treatments in Development for Multiple Sclerosis

8.7 Market Analysis for Multiple Sclerosis

8.7.1 United States

8.7.2 Europe

8.7.3 Japan

8.7.4 Rest of the World

8.8 Competitor Analysis for Multiple Sclerosis

9 Autoimmune Thyroid Disease

9.1 Pathology of Autoimmune Thyroid Disease

9.1.1 Types of Autoimmune Thyroid Disease

9.2 Risk Factors for Autoimmune Thyroid Disease

9.3 Prevalence of Autoimmune Thyroid Disease

9.4 Diagnostics for Autoimmune Thyroid Disease

9.5 Current Treatments for Autoimmune Thyroid Disease

9.6 Treatments in Development for Autoimmune Thyroid Disease

9.7 Market Analysis for Autoimmune Thyroid Disease

9.7.1 United States

9.7.2 Europe

9.7.3 Japan

9.7.4 Rest of the World

9.8 Competitor Analysis for Autoimmune Thyroid Disease

10 Sjogren’s Syndrome

10.1 Pathology of Sjogren’s Syndrome

10.2 Risk Factors for Sjogren’s Syndrome

10.3 Prevalence of Sjogren’s Syndrome

10.4 Diagnostics for Sjogren’s Syndrome

10.5 Current Treatments for Sjogren’s Syndrome

10.6 Treatments in Development for Sjogren’s Syndrome

10.7 Market Analysis for Sjogren’s Syndrome

10.7.1 United States

10.7.2 Europe

10.7.3 Japan

10.7.4 Rest of the World

10.8 Competitor Analysis for Sjogren’s Syndrome

11 Myasthenia Gravis

11.1 Pathology of Myasthenia Gravis

11.2 Risk Factors for Myasthenia Gravis

11.3 Prevalence of Myasthenia Gravis

11.4 Diagnostics for Myasthenia Gravis

11.4.1 Edrophonium Chloride (Tensilon) Test

11.4.2 Neostigmine Test

11.4.3 Antibodies Against Acetylcholine Receptor (AChR)

11.4.4 Electromyography Repetitive Nerve Stimulation (RNS)

11.4.5 Single Fiber Electromyogram (SFEMG)

11.5 Current Treatments for Myasthenia Gravis

11.5.1 Cholinesterase Inhibitors

11.5.2 Corticosteroids

11.5.3 Immunosuppressants

11.5.4 Plasmapheresis

11.5.5 Thymectomy

11.6 Treatments in Development for Myasthenia Gravis

11.7 Market Analysis for Myasthenia Gravis

11.7.1 United States

11.7.2 Europe

11.7.3 Japan

11.7.4 Rest of the World

11.8 Competitor Analysis for Myasthenia Gravis

12 Company Profiles

12.1 Abbott Laboratories

12.2 Abgenix, Inc.

12.3 Aventis Pharma AG

12.4 Berlex Laboratories, Inc.

12.5 Biogen, Inc.

12.6 Bristol-Myers Squibb Co.

12.7 Corixa Corp.

12.8 Elan Corporation, plc

12.9 Eli Lilly & Co.

12.10 Forest Laboratories, Inc.

12.11 Genelabs Technologies, Inc.

12.12 Genentech, Inc.

12.13 GlaxoSmithKline plc

12.14 ICN Pharmaceuticals, Inc.

12.15 Immune Response Corp.

12.16 Immunex Corp.

12.17 King Pharmaceuticals (Jones Pharma, Inc.)

12.18 LaJolla Pharmaceutical Co.

12.19 MGI Pharma, Inc.

12.20 Merck & Co., Inc.

12.21 Novartis Pharmaceuticals Corp.

12.22 Pharmacia Corp.

12.23 Roche Laboratories, Inc.

12.24 Salix Pharmaceuticals, Ltd.

12.25 Sanofi-Synthélabo SA

12.26 Schering-Plough Corp.

12.27 Serono SA

12.28 ZymoGenetics, Inc.

13 Company Directory

Abstract

And Theta’s new study, Autoimmune Disease Therapeutics Worldwide: Markets & Developments will answer your key market and R&D questions:

• What new treatments have already reached market? Are in development?
• What are the current and projected market sizes and shares for the treatments for each of these disorders?
• Which companies are developing new treatments? When will they reach the market? Will they be commerically successful?
• How is recent legislation and funding impacting R&D for these disorders?

Autoimmune Disease Therapeutics Worldwide covers the range of disorders, including: Rheumatoid arthritis Systemic lupus erythematosus Inflammatory bowel disease Psoriasis Multiple sclerosis Thyroid disease Sjogren’s syndrome Myasthenia gravis. Illustrated with detailed tables and full-color charts, Autoimmune Disease Therapeutics Worldwide cuts through the mass of raw data and gives you the value-added analysis to make the right decisions in this highly competitive market.

Please Note: Theta requires that, for PDF orders, clients sign a confidentiality agreement prior to fulfillment of PDF email delivery.

Get Full Details About This Report >>

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.